Valtech Cardio developed transcatheter heart valve technologies for the treatment of mitral and tricuspid valve regurgitation, including the Cardioband valve repair system.

In 2017, Valtech Cardio was acquired by Edwards Lifesciences, a U.S.-based global leader in structural heart innovation. The Cardiovalve transcatheter mitral valve replacement program was not included in the acquisition and was spun out into a separate company, Cardiovalve, which was later acquired by Venus Medtech, a China-based structural heart technology company.